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Abstract Melanin-concentrating hormone (MCH) is known to
act through two G-protein-coupled receptors MCHR1 and
MCHR2. MCHR1 has three potential sites (Asn13, Asn16 and
Asn23) for N-linked glycosylation in its extracellular amino-ter-
minus which may modulate its reactivity. Site-directed muta-
genesis of the rat MCHR1 cDNA at single or multiple combi-
nations of the three potential glycosylation sites was used to
examine the role of the putative carbohydrate chains on receptor
activity. It was found that all three potential N-linked glycosyl-
ation sites in MCHR1 were glycosylated, and that N-linked
glycosylation of Asn23 was necessary for full activity. Further-
more, disruption of all three glycosylation sites impaired proper
expression at the cell surface and receptor activity. These data
outline the importance of the N-linked glycosylation of the
MCHR1.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Melanin-concentrating hormone (MCH) is a 19-amino acid
cyclic peptide that was originally isolated from salmon pitui-
tary glands [1]. The rat counterpart was found in the hypo-
thalamus [2] and expressed mainly in the cell bodies of the
lateral hypothalamus and zona incerta with projections widely
distributed throughout the central nervous system [3]. In
mammals, MCH plays various biological roles, including the
central regulation of feeding behavior. Intracerebroventricular
administration of MCH promotes feeding behavior in rats
[4,5]. Targeted disruption of the MCH gene in mice results
in a lean phenotype as a result of hypophagia and increased
metabolic rate [5], whereas transgenic mice overexpressing
MCH are obese and insulin-resistant [6].
An orphan G-protein-coupled receptor (GPCR), originally
called SLC-1 [7], was identi¢ed as a cognate receptor of MCH
[8^12]. This receptor, presently named MCHR1, is expressed
in the brain at high levels [11,13,14] and in other regions at
low to moderate levels [11]. Cells transfected with MCHR1
responded to MCH by an increase in intracellular free Ca2þ
levels, inhibition of forskolin-stimulated cyclic AMP produc-
tion and activation of mitogen-activated protein kinase [10^
12,15]. A second MCH receptor, human MCHR2, was iso-
lated by sequence data mining [16], but several non-human
species, including Rodentia, do not have functional MCHR2
receptors [17]. A very recent study showed that MCHR1-de-
¢cient mice are lean, hyperactive, and hyperphagic and have
altered metabolism [18,19], suggesting that MCHR1 in mice
plays a role in energy homeostasis.
Glycosylation is a common posttranslational feature in the
GPCR superfamily. It has been shown that glycosylation of
the receptor may be involved in a variety of biological activ-
ities. These activities include maintenance of receptor stability,
folding, tra⁄cking of the receptor to the cell surface, ligand
binding, and signal transduction. We decided to analyze
whether glycosylation is also important for MCHR1 activity.
Western blot analysis of HEK293 cells transfected with
MCHR1 exhibited a broad 60-kDa band when MCHR1 is
detected with an antiserum against its C-terminus [13]. This
molecular weight is higher than that predicted from the
MCHR1 cDNA sequence, and may represent a glycosylated
form of the receptor. This is supported by the fact that the
presumed extracellular amino-terminal part of MCHR1 con-
tains three consensus sequences (Asn13, Asn16 and Asn23) that
would be suitable for N-glycosylation [7].
In this study, we prove that MCHR1 is indeed glycosylated.
we also analyze the functional role of the three putative N-gly-
cosylation sites of MCHR1 through suppression of N-glyco-
sylation with site-directed mutagenesis. We found that N-gly-
cosylation of MCHR1 at Asn23 is important for cell surface
expression, ligand binding and signal transduction.
2. Materials and methods
2.1. cDNA and mutagenesis
The incorporation of a sequence encoding the Flag epitope tag
before the ¢rst methionine in rat MCHR1 was performed by PCR.
The puri¢ed full-length cDNA of MCHR1 was subcloned into
pcDNA3.1 (Invitrogen, CA, USA). The generation of the construct
was con¢rmed by sequencing analysis. Oligonucleotide-mediated site-
directed mutagenesis was performed using a Quickchange site-directed
mutagenesis kit (Stratagene, CA, USA). The oligonucleotides were
designed to replace the asparagine residues at positions Asn13,
Asn16 and Asn23 with glutamine (Q) residues. Single-site mutations
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were ¢rst constructed. To elucidate the cumulative e¡ects of a lack of
glycosylation at multiple sites, three double receptor mutants,
N13,16Q, N13,23Q, and N16,23Q, were constructed. In the triple
mutant, all three potentially glycosylated asparagine residues, N13,
16, 23Q, were replaced with glutamine residues.
2.2. Cell culture and transfection
DNA was mixed with LipofectAMINE transfection reagents (Life
Technologies, MD, USA), and the mixture was diluted with Opti-
MEM and added to 60^70% con£uent HEK293T cells plated on
100-mm dishes [13]. The transfected cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing 10% fetal bovine se-
rum (FBS). Cell membranes were prepared from the cells for immu-
noprecipitation and Western blotting, and radioligand binding assay,
48 h after transfection. For the calcium in£ux assay, FACScan £ow
cytometric analysis and immunocytochemistry, the cells were passaged
to 96-well plates, 24-well plates, and cover slips, respectively, 24 h
after transfection and cultured for another 24 h at 37‡C.
2.3. Western blotting and immunoprecipitation
HEK293T cells were washed with phosphate-bu¡ered saline (PBS),
lysed with a rubber policeman in RIPA bu¡er (50 mM Tris^HCl, pH
8.0, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate
(SDS), 0.5% deoxycholate, 5 Wg/ml leupeptin, 5 Wg/ml aprotinin, and
0.5 mM PMSF) for 20 min at 4‡C, and the lysates cleared by centri-
fugation at 18 500Ug for 20 min at 4‡C. Aliquots of the cell lysates,
equivalent to 100 Wg protein, were treated with 0.7 U of peptide N-
glycosidase F (PNGase F, Boehringer Mannheim) for 3 h at 37‡C.
For cleavage with endoglycosidase H (Endo H, Boehringer Mann-
heim), the membrane preparation (100 Wg protein) in 15 Wl was mixed
with an equal volume of 50 mM sodium acetate (pH 4.8) with 120 Wg
SDS, and incubated with 10 mU of Endo H for 18 h at 37‡C. The
reactions were stopped by adding an equal volume of protein gel
loading bu¡er. For immunoprecipitation, an aliquot of the cell mem-
brane lysates (500 Wg protein) was precleaned with 30 Wl of protein-G-
agarose (50% suspension in PBS) at 4‡C for 30 min on a rotator. The
protein-G-agarose was then removed by centrifuging the lysates at
18 500Ug for 5 min at 4‡C. Subsequently, the precleaned cell mem-
brane lysates were incubated with 2 Wg of an anti-Flag M2 antibody
(Sigma, St. Louis, MO, USA) in protein-G-agarose for 15 h at 4‡C on
a rotator. The immune-complex was washed three times with RIPA
bu¡er and once with PBS, and subsequently eluted from the protein-
G-agarose by the addition of 30 Wl of protein gel loading bu¡er.
Proteins were separated in a 15% SDS^polyacrylamide gel electropho-
resis (PAGE) gel, and electro-transferred to a Hybond-P PVDF mem-
brane (Amersham International, Little Chalfont, UK). After blocking
with 5% skim milk dissolved in washing bu¡er (0.2% Tween 20 in
Tris^HCl bu¡ered saline), Flag-MCHR1 on the membrane was de-
tected using the M2 antibody (2 Wg/ml), followed by horseradish per-
oxidase-conjugated goat anti-mouse IgG antibody. The reactive bands
were visualized with ECL substrates (Amersham International).
2.4. FACScan £ow cytometric analysis for cell surface receptors
Transfected HEK293T cells in 24-well plates were ¢xed with 1%
paraformaldehyde for 10 min at room temperature, and incubated
with 8 Wg/ml anti-Flag M2 in PBS containing 20% FBS for 1 h.
The cells were washed three times with PBS and incubated with 10
Wg/ml £uorescein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG secondary antibody for 1 h. The cells were collected from the
wells with 5 mM EDTA and analyzed using a FACScan £ow cytom-
eter (Becton Dickinson Immunocytometer Systems, Inc.). Cells were
gated by light scatter or exclusion of propidium iodide, and 10 000
cells were acquired for each time point. The mean £uorescence of all
cells, minus the mean £uorescence of the cells with only the FITC-
conjugated second antibody, was used for the calculations.
2.5. Immuno£uorescence microscopy
Transfected HEK293T cells were ¢xed for 10 min in 3.7% parafor-
maldehyde in PBS. After two rinses with PBS, the cells were trans-
ferred, either with or without permeabilization (in 0.05% Triton X-100
in PBS for 15 min), into blocking solution (20% goat serum in PBS)
for 30 min [13], and then incubated with 8 Wg/ml anti-Flag M2 anti-
body for 1 h. The anti-Flag M2 antibody was detected using an
FITC-conjugated goat anti-mouse IgG secondary antibody (Alexa
Fluor 488, Molecular Probes). Fluorescent imaging was obtained
with TE300/Radiance2000 confocal microscopy (Bio-Rad).
2.6. Radioligand binding
Transfected HEK293T cells in suspension (8U105 cells) were incu-
bated with 1700 Bq [125I] (Phe13, Tyr19) MCH (Amersham Interna-
tional) in the absence (total binding) or presence (non-speci¢c bind-
ing) of 1 WM non-labeled MCH (Peptide Institute, Osaka, Japan) in
0.3 ml DMEM supplemented with 50 mM HEPES and 2% BSA for
2 h at 4‡C with gentle shaking. Subsequently, the entire contents of
the cells were ¢ltered using a GF/C ¢lter presoaked with 0.3% poly-
ethyleneimine and the ¢lter was washed three times with 1 ml of PBS.
The radioactivity on the ¢lter was counted using a Q-counter. Speci¢c
binding was de¢ned as the di¡erence between the total binding and
the non-speci¢c binding.
2.7. Measurement of calcium in£ux
Transfected HEK293T cells seeded on black-walled 96-well plates
(Becton Dickinson, NJ, USA) were loaded for 1 h at 37‡C with a non-
wash calcium dye (Calcium assay kit, Molecular Device, CA, USA) in
Hanks’ balanced salt solution containing 20 mM HEPES (pH 7.5).
The level of [Ca2þ]i was then detected using a Flexstation imaging
plate reader (Molecular Device) over a 150-s stimulation period at
each concentration of MCH. Data were expressed as £uorescence
(arbitrary units) versus time. The EC50 values for MCH were calcu-
lated by curve ¢tting with the program SOFTmax Pro (Molecular
Device).
3. Results
3.1. Western blot analysis of Flag-MCHR1 and the mutants
Previously we used an anti-MCHR1 antibody against the
carboxy-terminal region (Bachem, Germany) to identify
MCHR1 in the transfected cells [20], but this commercial
antibody was not suitable for Western blotting. Therefore,
we transfected amino-terminal Flag-tagged MCHR1 (Flag-
MCHR1) into HEK293T cells in order to identify the full-
length MCHR1. In the control calcium in£ux assays, non-
tagged MCHR1 and Flag-MCHR1 were found to have sim-
ilar EC50 values for MCH (data not shown), indicating that
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Fig. 1. Expression of Flag-MCHR1 and mutant receptors in
HEK293T cells. A: Transfected cells were lysed and 50 Wg total
protein was separated by 15% SDS^PAGE, transferred to PVDF
membranes and immunoblotted with the anti-Flag M2 antibody.
The cell extracts transfected with Flag-MCHR1 were treated with
peptide N-glycosidase F (N-Gly) or Endo H. The lowermost band
is a non-speci¢c one which reacted with the anti-Flag M2 antibody.
B: Immunoprecipitation of cell lysates by the anti-Flag M2 anti-
body. N13Q and N13,23Q showed a similar molecular weight to
N16Q and N16,23Q, respectively.
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the addition of the Flag tag did not a¡ect the receptor func-
tion. Next Flag-MCHR1 was analyzed by Western blotting
using an anti-Flag M2 antibody. The result, shown in Fig. 1A,
exhibited several characteristic immunoreactive bands of ap-
proximately 35^65 kDa. After enzymatic deglycosylation of
Flag-MCHR1 expressed in HEK293T cells with PNGase F,
a shift to distinct lower molecular weight bands was observed
(Fig. 1A). This indicates the presence of oligosaccharides that
were modi¢ed in the Golgi (complex or hybrid type) in
MCHR1. Moreover, glycosylation of MCHR1 by Endo H-
sensitive oligosaccharides modi¢ed in the ER (high mannose
type) was also observed although there were several MCHR1
bands in the Western blotting.
The predicted amino acid sequence of MCHR1 reveals
N13, 16, 23Q(-TX-100)
N13, 16, 23Q(+TX-100)F-MCHR1(+TX-100)
F-MCHR1(-TX-100)
Fig. 2. Cell surface expression and speci¢c radioligand binding of Flag-MCHR1 and mutant receptors. The results are meansTS.E.M. of three
independent experiments. *P6 0.05, **P6 0.01 compared with Flag-MCHR1 by students t-test. A: Flow cytometric analysis of the cell surface
expression of the mutant receptors using the anti-Flag M2 antibody. The percentage with respect to Flag-MCHR1 (100%) was calculated for
each mutant. B: Speci¢c radioligand binding of [125I] (Phe13, Tyr19) MCH to transfected cells in suspension. Non-speci¢c binding was quanti-
¢ed in the presence of 1 WM unlabeled MCH. C: Cellular localization of Flag-MCHR1 and N13,16,23Q by immuno£uorescence staining with
the anti-Flag M2 antibody and confocal microscopy. The cell surface expression was compared using transfected non-permeabilized cells (a,b)
and permeabilized cells (c,d). Vector-transfected cells incubated with the anti-Flag M2 antibody showed no signi¢cant staining (data not
shown). Bar= 10 Wm.
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three potential sites for N-glycosylation at Asn13, Asn16 and
Asn23 which are part of consensus sequence (-NXS/T-) [7]. To
determine whether these sites are glycosylated, we constructed
three MCHR1 mutants in which each of the three asparagine
residues was replaced by a glutamine residue. Western blot
analysis revealed that mutated receptors at N13Q and N16Q
had similar characteristics to those of the wild type Flag-
MCHR1, except that the appearance of the 42-kDa band
was decreased, while N23Q produced di¡erent features, where
the uppermost bands were lost (Fig. 1B). These ¢ndings in-
dicate that all three potential N-linked glycosylation sites in
MCHR1 were glycosylated, but that there was greater glyco-
sylation at Asn23 compared with Asn13 or Asn16. This was
further demonstrated by the immunoprecipitation products,
in that N23Q migrated faster than N16Q (Fig. 1B). All the
double mutants, N13,16Q, N13,23Q and N16,23Q, had reduc-
tions of the apparent lower molecular weight bands compared
with those of Flag-MCHR1 (Fig. 1A). After immunoprecipi-
tation, the uppermost band in N16,23Q was decreased, while
the band was clearly present in N13,16Q (Fig. 1B). Finally,
the N13,16,23Q receptor, in which all three glycosylation sites
were mutated, revealed the same molecular mass as the degly-
cosylated product after PNGase F treatment (Fig. 1A). This
shows that N13,16,23Q was non-glycosylated MCHR1.
3.2. Cell surface expression of MCHR1 mutant receptors and
ligand-binding properties
Cell surface expression of Flag-MCHR1 and the mutant
receptors was quanti¢ed by FACScan £ow cytometric analysis
of Flag expression, as shown in Fig. 2A. No signi¢cant
change was detected in the cell surface expression of the single
mutants, N13Q and N16Q, whereas the expression of N23Q
was signi¢cantly decreased by 25%. The expression of the
double mutant receptors N13,16Q, N13,23Q and N16,23Q
at the cell surface were decreased by 30^35%, and there
were no signi¢cant di¡erences among them. In the non-glyco-
sylated mutant, N13,16,23Q, the expression was dramatically
decreased by 62%.
Analysis of Flag localization in non-permeabilized cells by
confocal microscopy demonstrated that both Flag-MCHR1
and the mutant receptor N13,16,23Q were distinctly localized
to the plasma membrane. However, the relative intensity of
the membrane localization appeared to be reduced in the
N13,16,23Q mutant compared with Flag-MCHR1 (Fig. 2C).
This is consistent with the analysis by £ow cytometry de-
scribed above. In permeabilized cells, the N13,16,23Q mutant
showed a distinct perinuclear labeling pattern, while N23Q
and all the double mutants were localized to the plasma mem-
brane but not to the perinuclear region (data not shown).
To examine whether the expression levels were responsible
for the binding of the mutant receptors, we compared the
ligand binding levels of Flag-MCHR1 and the mutant recep-
tors. In cells expressing N23Q, speci¢c binding of [125I] (Phe13,
Tyr19) MCH was signi¢cantly reduced by 40%, although the
radioligand binding in N13Q and N16Q was unchanged (Fig.
2B). The speci¢c radioligand binding in all the double mutants
was reduced by 60% compared with that of Flag-MCHR1.
Finally, even in the total absence of the consensus N-glyco-
sylation sites, N13,16,23Q still bound MCH, but the speci¢c
binding was exclusively decreased by 72%.
3.3. E¡ect of glycosylation on MCH-induced calcium in£ux
The mutant receptors were further characterized for their
abilities to cause calcium in£ux after stimulation with MCH
(Fig. 3). Both N13Q and N16Q produced slightly higher EC50
values for MCH in calcium in£ux, while N23Q had more than
two-fold higher EC50 values for MCH compared with that of
Flag-MCHR1 (23 nM versus 58 nM MCH for Flag-MCHR1
and N23Q, respectively). Interestingly, the double mutant
N13,16Q had a similar response to the single mutant N23Q,
whereas the other double mutants, N13,23Q and N16,23Q,
had higher EC50 values than that of N13,16Q (108 nM versus
58 nM MCH for N13,23Q and N13,16Q, respectively). The
non-glycosylated mutant, N13,16,23Q showed eight-fold high-
er EC50 values (190 nM MCH for N13,16,23Q). Thus, among
the double mutants, the potency in MCH-induced calcium
Fig. 3. MCH-stimulated calcium in£ux in HEK293T cells expressing Flag-MCHR1 or the mutant receptors. The EC50 values are meansT
S.E.M. of at least three independent experiments.
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in£ux appears not to be relative to the extent of cell surface
expression and radioligand binding receptor glycosylation
(Fig. 2A,B). The single mutants, N13Q, N16Q, and N23Q,
and the double mutant N13,16Q did not alter the maximal
response of the cumulative £uorescence units caused by 3 WM
MCH. However, in N13,23Q, N16,23Q and N13,16,23Q, the
maximal response was signi¢cantly decreased by 30%, 35%,
and 45%, respectively.
4. Discussion
The importance of N-linked glycosylation for expression
and function has been studied for many GPCRs. Most of
the GPCRs of the large rhodopsin subfamily that includes
adrenergic receptors and a number of peptide receptors have
relatively short extracellular amino-terminals with one or
more putative glycosylation sites, but the role of the N-glyco-
sylation is somewhat variable. In some [21], glycosylation of
at least one site is required for e⁄cient cell surface expression
and signal transduction, while in others [22^25], glycosylation
at speci¢c residues is crucial for correct delivery to the cell
surface and/or signal transduction. In contrast, the non-gly-
cosylated V2 vasopressin receptor was shown to be fully ac-
tive for ligand binding and signal transduction [26].
Our approach involved mutagenesis of the MCHR1 recep-
tor cDNA to delete the glycosylation sequences in the amino-
terminal region, and testing of the resulting molecules for
their interaction with the ligand and signal transduction in
the transfection system. This study has demonstrated that
all of the three potential glycosylation sites of the MCHR1
receptor are glycosylated, and that the sites are not equally
relevant for cell surface expression, ligand binding, and MCH-
stimulated calcium in£ux of MCHR1. Single mutation of the
asparagines at positions 13 or 16 did not impair the level of
cell surface expression of the receptor, radioligand binding or
the ability for MCH-mediated calcium in£ux. Therefore, the
carbohydrate moiety at each single glycosylation site at 13 or
16 is not absolutely required for active MCHR1 on the cell
surface. Conversely, substitution of Asn23 signi¢cantly low-
ered the cell surface expression, ligand binding, and potency
for MCH-stimulated calcium in£ux compared with Flag-
MCHR1, indicating that the glycosylation at Asn23 is required
for optimal expression and function of MCHR1 on the cell
surface.
The importance of the glycosylation at Asn23 is also indi-
cated by the results of the other mutants. The double mutant
N13,16Q exhibited reduced glycosylation compared with the
single mutant N23Q in Western blotting (Fig. 1A,B), and
there were signi¢cant di¡erences between them in both the
cell surface expression and radioligand binding (Fig. 2A,B,
P6 0.05, respectively). However, no di¡erence in the ability
to cause calcium in£ux was observed between in N23Q
and N13,16Q (Fig. 3). We created other mutants in which
the asparagine residues were replaced by alanine (N23A,
N13,16A). These gave similar EC50 values for MCH in cal-
cium in£ux to N23Q and N13,16Q, respectively (data not
shown), making it less likely that the replacement of aspara-
gine with glutamine had a signi¢cant in£uence on the func-
tional activity of MCHR1. The double mutants N13,16Q,
N13,23Q and N16,23Q showed a similar phenotype in terms
of the cell surface expression and radioligand binding (Fig.
2A,B). However, the double mutants with the amino acid
replacement at Asn23 (N13,23Q and N16,23Q) had a lower
potency to cause MCH-stimulated calcium in£ux than that of
N13,16Q (Fig. 3). Again, these results suggest the functional
importance of glycosylation at Asn23 for signal transduction
in MCHR1. This has also been observed in other GPCRs.
For example, rhodopsin is glycosylated at Asn2 and Asn15,
and mutations at or near Asn2 had little e¡ect on cell surface
expression and GT activation [22]. In contrast, mutations
near Asn15 resulted in poor activation of signal transduc-
tion. In the secretin receptor, among single mutations at
the ¢ve potential glycosylation sites, only the Asn72 mutation
was found to impair the biological activity of the receptor
[23].
Previous studies have demonstrated that the loss of carbo-
hydrate moieties associated with membrane receptors led to
reduced cell surface expression [21,24,27,28]. In agreement
with these reports, progressive disruption of the glycosylation
sites of MCHR1 caused a progressive reduction in the cell
surface expression as re£ected in the FACScan £ow cytomet-
ric analysis (Fig. 2A). In membrane-permeabilized cells, non-
glycosylated MCHR1, N13,16,23Q, was distinctly expressed
in the perinuclear region (Fig. 2C). It appears that the glyco-
sylation of MCHR1 plays a role in its correct translocation
through the ER and Golgi apparatus to the plasma membrane
[27,28]. However, elimination of one or two of the glycosyla-
tion sites did not impair the tra⁄cking of the receptor, and
thus all the other MCHR1 mutants were correctly delivered to
the plasma membrane as visualized by confocal microscopy.
This suggests that glycosylation of at least one site may be
su⁄cient for normal intracellular tra⁄cking of MCHR1. This
is consistent with the human VIP 1 and secretin receptors
[23,24]. Thus, the reduced membrane expression observed in
the other mutants (N23Q and the double mutants) is not due
to changes in the delivery, but might rather be related to
changes in the structure of the receptor. These conformational
changes may result in the lower potency for ligand binding
and MCH-stimulated calcium in£ux. It is possible that the
amount of sugar moieties is not su⁄cient to constrain the
amino acid residues of the amino-terminus in a conformation
that is optimal for MCH binding. Further physical studies
with nuclear magnetic resonance spectroscopy or X-ray crys-
tallography will be required to resolve the three-dimensional
structure of the MCHR1^MCH complex and the role of the
sugar moieties.
In conclusion, all of the potential N-glycosylation sites,
Asn13, Asn16 and Asn23, in MCHR1 are glycosylated. N-gly-
cosylation of MCHR1, particularly at Asn23, seems to play
roles in the cell surface expression, ligand binding, and signal
transduction of MCHR1 to display the full activity of the
receptor. The mechanism of how glycosylation at the ami-
no-terminus can e¡ect events throughout the receptor, includ-
ing events at distal regions such as the carboxy terminus, is
unclear but indicates a further complexity through which the
cell can regulate its responses to GPCR activation.
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